Concepción Fernández‐Chacón

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17

Mesothelial‐to‐mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer

Ángela Rynne‐Vidal, Chi Lam Au‐Yeung, José A. Jiménez‐Heffernan et al. · The Journal of Pathology · 2017 · 112 citations · Full text

Medicine, Cancer Biology, Oncology +17

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)

Miguel Gil‐Gil, Gaspar Reynés, Carmen Balañá et al. · Anti-Cancer Drugs · 2012 · 42 citations

Medicine, Oncology, Pharmacotherapy +17

Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805

M. Martin, Aňa Lluch, Miguel Ángel Seguí et al. · Journal of Clinical Oncology · 2005 · 15 citations

Medicine, Oncology, Pharmacotherapy +17